Evidence map›Paper›PMID 40310574›Full record

ArticleInternational journal of hematology2025

A case of acute promyelocytic leukemia complicated by mitochondrial disease.

Yukari Sakurai, Masakatsu Yanagimachi, Mieko Ito, Ayana Hirose, Naoyuki Miyagawa, Dai Keino, Tomoko Yokosuka, Fuminori Iwasaki, Satoshi Hamanoue, Masae Shiomi and 3 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yukari SakuraiDivision of Hematology/Oncology, Kanagawa Children's Medical Center, 138-4 Mutsukawa-2 Chome, Minami-Ku, Yokohama, Kanagawa, 232-8555, Japan. yukari5p@asahikawa-med.ac.jp.ORCID http://orcid.org/0000-0002-5541-7212
Masakatsu YanagimachiDivision of Hematology/Oncology, Kanagawa Children's Medical Center, 138-4 Mutsukawa-2 Chome, Minami-Ku, Yokohama, Kanagawa, 232-8555, Japan.
Mieko ItoDivision of Hematology/Oncology, Kanagawa Children's Medical Center, 138-4 Mutsukawa-2 Chome, Minami-Ku, Yokohama, Kanagawa, 232-8555, Japan.
Ayana HiroseDivision of Hematology/Oncology, Kanagawa Children's Medical Center, 138-4 Mutsukawa-2 Chome, Minami-Ku, Yokohama, Kanagawa, 232-8555, Japan.
Naoyuki MiyagawaDivision of Hematology/Oncology, Kanagawa Children's Medical Center, 138-4 Mutsukawa-2 Chome, Minami-Ku, Yokohama, Kanagawa, 232-8555, Japan.
Dai KeinoDivision of Hematology/Oncology, Kanagawa Children's Medical Center, 138-4 Mutsukawa-2 Chome, Minami-Ku, Yokohama, Kanagawa, 232-8555, Japan.
Tomoko YokosukaDivision of Hematology/Oncology, Kanagawa Children's Medical Center, 138-4 Mutsukawa-2 Chome, Minami-Ku, Yokohama, Kanagawa, 232-8555, Japan.
Fuminori IwasakiDivision of Hematology/Oncology, Kanagawa Children's Medical Center, 138-4 Mutsukawa-2 Chome, Minami-Ku, Yokohama, Kanagawa, 232-8555, Japan.
Satoshi HamanoueDivision of Hematology/Oncology, Kanagawa Children's Medical Center, 138-4 Mutsukawa-2 Chome, Minami-Ku, Yokohama, Kanagawa, 232-8555, Japan.
Masae ShiomiDivision of Hematology/Oncology, Kanagawa Children's Medical Center, 138-4 Mutsukawa-2 Chome, Minami-Ku, Yokohama, Kanagawa, 232-8555, Japan.
Shoko GotoDivision of Hematology/Oncology, Kanagawa Children's Medical Center, 138-4 Mutsukawa-2 Chome, Minami-Ku, Yokohama, Kanagawa, 232-8555, Japan.
Tomohide GotoDivision of Pediatric Neurology, Kanagawa Children's Medical Center, Yokohama, Japan.
Hiroaki GotoDivision of Hematology/Oncology, Kanagawa Children's Medical Center, 138-4 Mutsukawa-2 Chome, Minami-Ku, Yokohama, Kanagawa, 232-8555, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 15-year-old boy with congenital mitochondrial disease was diagnosed with acute promyelocytic leukemia. He was treated with all-trans retinoic acid, and his anthracycline dose was reduced in response to his underlying condition. He successfully achieved molecular remission and maintained this state for 4 years. In vitro drug sensitivity testing in peripheral mononuclear cells suggests that samples from patients in remission show higher sensitivity to various anticancer drugs than samples from healthy volunteers. Reduced-dose chemotherapy could be a valid treatment option for patients with mitochondrial diseases because exposure to elevated oxidative stress may contribute to increased drug sensitivity in these patients.

Indexed as

Leukemia, Promyelocytic, AcuteMitochondrial DiseasesAdolescentAnthracyclinesAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleTretinoinAnthracyclinesAntineoplastic AgentsTretinoinAcute promyelocytic leukemiaAnthracyclineMitochondrial diseaseOxidative stressReactive oxygen species

Identifiers

PMID40310574
PMCPMC12304024

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.